MedPharm Expands US Center of Excellence
Pharmaceutical Technology's In the Lab eNewsletter
The company will invest $4 million to increase topical and transdermal formulation development and performance testing services at its Durham, NC, facility.
On Jan. 11, 2019, MedPharm, a contract provider of topical and transdermal product design and formulation development services, announced the $4-million expansion of its center of excellence in Durham, NC.
The expansion creates additional laboratory space for development programs and topical dosage formulation development services and performance testing on topical and transdermal pharmaceutical products. The company reports that the investment in facility expansion and equipment will more than triple the existing footprint of the facility to 25,000 ft2.
Additionally, the company has increased its liquid chromatography–mass spectrometry (LC/MS) capacity and the automation of sample handling. As part of the investment, MedPharm has installed the latest Waters LC-MS/MS for bio-analysis. This new model is equipped with the latest ultra-performance liquid chromatography for rapid separation and method development and offers mass spectrometry detection at picogram levels, according to MedPharm.
“This expansion aligns with MedPharm’s strategy to keep increasing the sophistication and relevance of our proprietary ex-vivo human skin models and further increase our responsiveness to clients in formulation development, especially in ocular delivery,” said Eugene Ciolfi, MedPharm’s president and CEO, in a company press release. “The expansion complements the recent expansion we have completed in our facility at our headquarters in Guildford, UK, and reflects the positive demand for our services globally.”
Source: MedPharm
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
